China’s NMPA grants approval to products from Zydus and Glenmark.
Zydus Lifesciences and Glenmark Pharmaceuticals have both received approvals from China's National Medical Products Administration (NMPA) for their respective products. Zydus Lifesciences has been granted approval for Venlafaxine Extended-Release (ER) Capsules, 75 mg...
Indian pharmaceutical companies Cipla, Natco, Hetero, and Annora have secured major contracts to supply generic drugs to the Chinese market.
Cipla, Natco, Hetero, and Annora, four prominent Indian pharmaceutical companies, have secured significant contracts to supply generic drugs to China. This development marks a major breakthrough for Indian pharmaceutical companies in the Chinese market. The contracts...
Sun Pharma Secures Rs 828 Crore Refund as CESTAT Declares Revenue Department’s Demand as Legally Invalid
Sun Pharmaceutical Industries, one of India's largest pharmaceutical companies, has won a significant excise refund battle. The Customs, Excise, and Service Tax Appellate Tribunal (CESTAT) ruled in favor of Sun Pharma, dismissing a revenue demand of Rs 828 crore...
Lupin Announces Robust Product Pipeline and Key Strategic Objectives – scanx.trade
Lupin, a leading pharmaceutical company, has unveiled its ambitious product pipeline and strategic targets, showcasing its commitment to driving growth and innovation in the industry. The company has outlined a robust pipeline of new products and formulations, aimed...
Hospitals pioneer a greener future in healthcare, driving the shift towards eco-friendly medical practices.
The healthcare sector is facing a paradox in its approach to protecting life. While its primary principle is "primum non nocere" or "first, do no harm," the sector itself is contributing to the climate crisis, which is having a devastating impact on human health. The...
Zydus secures tentative USFDA approval for its 100mg and 150mg Olaparib Tablets.
Zydus Lifesciences Limited, an Indian pharmaceutical company, has received tentative approval from the United States Food and Drug Administration (USFDA) for its Olaparib Tablets, 100 mg and 150 mg. This medication is used to treat certain types of ovarian, breast,...
Motilal Oswal Reiterates ‘Buy’ Rating on Piramal Pharma Amid Short-Term Challenges; Analyzes Q2 Earnings – NDTV Profit
Motilal Oswal has maintained a "buy" rating on Piramal Pharma despite the company facing near-term headwinds. The brokerage firm reviewed Piramal Pharma's Q2 results and noted that the company's performance was impacted by one-time items and supply chain disruptions....
Lupin Bioresearch Center receives a flawless report with zero observations from the USFDA following a successful inspection and evaluation.
The Lupin Bioresearch Center, a prominent research facility, has achieved a significant milestone by receiving zero observations from the United States Food and Drug Administration (USFDA) following a successful inspection and assessment. This impressive feat...
Sun Pharma Secures Rs 828 Crore Refund as CESTAT Declares Revenue Department’s Demand as Legally Invalid
Sun Pharmaceutical Industries, one of India's largest pharmaceutical companies, has won a significant excise refund battle. The Customs, Excise, and Service Tax Appellate Tribunal (CESTAT) ruled in favor of Sun Pharma, dismissing a revenue demand of Rs 828 crore...
Sun Pharma’s US revenue from innovative medicines now exceeds that of its generic offerings.
Sun Pharmaceutical Industries Ltd. has reported a significant shift in its business mix, with innovative medicines outpacing generic drug sales in the United States during the second quarter of fiscal year 2026. The company's innovative medicines, including Ilumya,...
Sun Pharma’s Q2 net profit has increased by 2.5% to ₹3,118 crore, with a 9% year-over-year revenue growth, despite a 4.1% decline in US sales.
Sun Pharmaceutical Industries has announced its Q2 results, showing a 2.5% increase in net profit to ₹3,118 crore. The company's revenue growth stood at 9% year-over-year (YoY), driven by strong performance in the domestic market and emerging markets. However, US...
Next week, several major companies, including Airtel, LIC, SBI, M&M, Sun Pharma, and Titan, are set to release their Q2 earnings reports.
The Indian corporate sector has reported earnings in line with expectations for the September quarter, boosting market sentiment. Several prominent companies, including Indian Oil Corporation, Adani Green Energy, and Hindustan Petroleum Corporation Limited, have...
Delhi High Court grants interim relief to Sun Pharma in trademark dispute, restraining Alenvision from selling its NEXADOM medication amidst allegations of infringing on Sun Pharma’s NAXDOM trademark.
The Delhi High Court has granted interim relief to Sun Pharma in a trademark dispute over the name "NAXDOM". The court has barred Alenvision from manufacturing and selling a drug called "NEXADOM", which Sun Pharma claims is deceptively similar to their trademarked...
Dr Sharvil Patel of Zydus Lifesciences assumes the role of President at the Indian Pharmaceutical Association
Zydus Lifesciences' Managing Director, Dr. Sharvil Patel, has taken over as the new President of the Indian Pharmaceutical Alliance (IPA). The IPA is a coalition of Indian pharmaceutical companies that aims to promote the interests of the domestic pharmaceutical...
China’s reduction in import duties helps alleviate the impact of US tariffs on India’s pharmaceutical industry.
The Indian pharmaceutical industry is facing a complex global trade landscape, with contrasting developments in China and the US. China has reduced import duties on Indian pharma products by 30%, effectively enabling near-zero-cost access, providing a significant...
Five pharmaceutical companies, including Sun Pharma and Zydus, have issued recalls for their products in the US market.
Sun Pharma, Zydus, and three other pharmaceutical companies have issued recalls for their products in the US market. The recalls were initiated due to various reasons, including contamination, labeling issues, and deviations from manufacturing standards. Sun Pharma,...
Indian pharmaceutical companies Cipla, Natco, Hetero, and Annora have secured major contracts to supply generic drugs to the Chinese market.
Cipla, Natco, Hetero, and Annora, four prominent Indian pharmaceutical companies, have secured significant contracts to supply generic drugs to China. This development marks a major breakthrough for Indian pharmaceutical companies in the Chinese market. The contracts...
Delhi High Court’s Decision in F. Hoffmann-La Roche Ag & Anr. v. Natco Pharma – Cyril Amarchand Mangaldas
The Delhi High Court recently delivered a significant judgment in the case of F. Hoffmann-La Roche Ag & Anr. vs. Natco Pharma, which has far-reaching implications for the pharmaceutical industry. The court's ruling pertains to the interpretation of Section 107A of the...
NATCO Pharma Limited’s ability to maintain steady cash flow during economic downturns is being reassessed.
NATCO Pharma Limited is an Indian pharmaceutical company that has been facing challenges in maintaining stable cash flow during market downturns. According to recent statistics, the company's cash flow has been volatile, with significant fluctuations in its operating...
The Supreme Court has granted Natco permission to market a generic version of Risdiplam.
The Supreme Court of India has rejected a plea by Swiss pharmaceutical company F. Hoffmann-La Roche AG (Roche) to restrain Natco Pharma Ltd from selling a generic version of its life-saving spinal muscular atrophy (SMA) drug, Risdiplam, in India. The court upheld a...
Natco Pharma set to purchase major shareholding in South African company Adcock Ingram
India's Natco Pharma has announced a significant investment in South Africa's 135-year-old pharmaceutical giant, Adcock Ingram. The R 4.2-billion deal will see Adcock Ingram become a privately-held entity co-owned by Natco and Bidvest, with Bidvest remaining the...
Natco Pharma considers splitting off its agricultural division.
Natco Pharma, a generic drugmaker, is considering spinning off its agro business into a separate entity. The company's board of directors has given in-principle approval for the demerger, which is expected to unlock value in the core pharmaceuticals business and Drive...
Rajiv Nannapaneni, the CEO of Natco Pharma
Rajiv Nannapaneni, CEO of Natco Pharma, believes that the Indian pharma sector is not threatened by the recent US trade tariffs. He attributes this to the fact that the US consumes 92% of Indian generic drugs, making it reliant on Indian pharmaceuticals. Nannapaneni...
Indian generic companies intensify challenge to Novo Nordisk’s weight-loss medication patent
A patent battle is unfolding in India between Danish pharmaceutical company Novo Nordisk and Indian pharmaceutical companies, particularly Hyderabad-based Natco Pharma. The dispute centers around Novo Nordisk's blockbuster weight-loss drug, semaglutide, which is sold...
China’s NMPA grants approval to products from Zydus and Glenmark.
Zydus Lifesciences and Glenmark Pharmaceuticals have both received approvals from China's National Medical Products Administration (NMPA) for their respective products. Zydus Lifesciences has been granted approval for Venlafaxine Extended-Release (ER) Capsules, 75 mg...
Indian pharmaceutical companies Cipla, Natco, Hetero, and Annora have secured major contracts to supply generic drugs to the Chinese market.
Cipla, Natco, Hetero, and Annora, four prominent Indian pharmaceutical companies, have secured significant contracts to supply generic drugs to China. This development marks a major breakthrough for Indian pharmaceutical companies in the Chinese market. The contracts...
Sun Pharma Secures Rs 828 Crore Refund as CESTAT Declares Revenue Department’s Demand as Legally Invalid
Sun Pharmaceutical Industries, one of India's largest pharmaceutical companies, has won a significant excise refund battle. The Customs, Excise, and Service Tax Appellate Tribunal (CESTAT) ruled in favor of Sun Pharma, dismissing a revenue demand of Rs 828 crore...
Lupin Announces Robust Product Pipeline and Key Strategic Objectives – scanx.trade
Lupin, a leading pharmaceutical company, has unveiled its ambitious product pipeline and strategic targets, showcasing its commitment to driving growth and innovation in the industry. The company has outlined a robust pipeline of new products and formulations, aimed...
Hospitals pioneer a greener future in healthcare, driving the shift towards eco-friendly medical practices.
The healthcare sector is facing a paradox in its approach to protecting life. While its primary principle is "primum non nocere" or "first, do no harm," the sector itself is contributing to the climate crisis, which is having a devastating impact on human health. The...
Zydus secures tentative USFDA approval for its 100mg and 150mg Olaparib Tablets.
Zydus Lifesciences Limited, an Indian pharmaceutical company, has received tentative approval from the United States Food and Drug Administration (USFDA) for its Olaparib Tablets, 100 mg and 150 mg. This medication is used to treat certain types of ovarian, breast,...
Motilal Oswal Reiterates ‘Buy’ Rating on Piramal Pharma Amid Short-Term Challenges; Analyzes Q2 Earnings – NDTV Profit
Motilal Oswal has maintained a "buy" rating on Piramal Pharma despite the company facing near-term headwinds. The brokerage firm reviewed Piramal Pharma's Q2 results and noted that the company's performance was impacted by one-time items and supply chain disruptions....
Lupin Bioresearch Center receives a flawless report with zero observations from the USFDA following a successful inspection and evaluation.
The Lupin Bioresearch Center, a prominent research facility, has achieved a significant milestone by receiving zero observations from the United States Food and Drug Administration (USFDA) following a successful inspection and assessment. This impressive feat...
Indian pharmaceutical companies Cipla, Natco, Hetero, and Annora have secured major contracts to supply generic drugs to the Chinese market.
Cipla, Natco, Hetero, and Annora, four prominent Indian pharmaceutical companies, have secured significant contracts to supply generic drugs to China. This development marks a major breakthrough for Indian pharmaceutical companies in the Chinese market. The contracts...
Eli Lilly’s Mounjaro achieves ₹1 billion in monthly sales in India’s pharma market through partnership with Cipla.
Eli Lilly's diabetes medication, Mounjaro, has achieved unprecedented success in India's pharmaceutical market, crossing ₹1 billion in monthly sales. This remarkable feat is a result of the company's strategic partnership with Cipla, a leading Indian pharmaceutical...
Cipla Limited Announces Acquisition of 100% Stake in Inzpera Healthsciences at ₹110.65 Crore – geneonline.com
Cipla Limited, a leading pharmaceutical company, has announced its plans to acquire a 100% stake in Inzpera Healthsciences Private Limited, a healthcare startup, for a consideration of ₹110.65 crore. This acquisition is expected to strengthen Cipla's presence in the...
Cipla appoints Achin Gupta as its new CEO, effective April 2026, in addition to his current role as Chief Operating Officer.
Indian pharmaceutical company Cipla Ltd has announced a change in its leadership, with current Chief Operating Officer (COO) Achin Gupta set to take over as the company's next Chief Executive Officer (CEO) and Managing Director. Gupta will succeed Umang Vohra, who has...
Cipla names Achin Gupta as new Managing Director and Global Chief Executive Officer, set to take office on April 1, 2026.
Cipla Limited, a leading pharmaceutical company, has announced the appointment of Achin Gupta as its new Managing Director and Global Chief Executive Officer (MD & GCEO), effective April 1, 2026. Gupta will succeed Umang Vohra, who has led the company since 2016. This...
Cipla Health ventures into sexual wellness sector with introduction of Unfold brand
Cipla Health, a leading consumer healthcare company in India, has launched a new brand called Unfold, which marks its entry into the sexual wellness category. Unfold aims to promote openness, trust, and choice in intimate wellbeing, and its visual identity was...
Cipla Health and MullenLowe’s dCell launch new brand focused on sexual wellness
Cipla Health, a leading healthcare company, has launched a new brand called Unfold, marking its entry into the sexual wellness segment. The brand's design and visual identity were developed by dCell, a design agency, to redefine how intimacy is represented in India's...
Cipla Enters India’s Weight-Loss Segment with ‘Yurpeak’, a Repurposed Version of Mounjaro
India's weight-loss market has welcomed a new player with the launch of 'Yurpeak' by Cipla, a popular pharmaceutical company. Yurpeak is the brand name given to the medication Mounjaro, which has been approved by the US FDA for the treatment of type 2 diabetes....
Hospitals pioneer a greener future in healthcare, driving the shift towards eco-friendly medical practices.
The healthcare sector is facing a paradox in its approach to protecting life. While its primary principle is "primum non nocere" or "first, do no harm," the sector itself is contributing to the climate crisis, which is having a devastating impact on human health. The...
Navi Mumbai airport has collaborated with Apollo Hospitals to establish a 24-hour on-site medical facility equipped with ICU ambulances.
Navi Mumbai International Airport (NMIA) has partnered with Apollo Hospitals to establish a 24x7 on-site medical centre at the airport. The medical centre will provide comprehensive medical care to passengers, staff, and visitors at the airport. The partnership aims...
Apollo Cradle Organizes its 3rd Annual National Conference in 2025
The 3rd National Cradle Conference (NCC 2025) was recently held in New Delhi, India, on November 1st and 2nd, 2025. The two-day conference was organized by Apollo Cradle and Apollo Fertility, and it brought together the country's most renowned experts in maternal,...
Apollo doctor weighs in: High AQI – to run outdoors or stay in? A 2-step plan to breathe easy
As air quality levels continue to deteriorate in Indian cities, fitness enthusiasts are becoming increasingly concerned about the safety of exercising outdoors when the Air Quality Index (AQI) is poor. Dr. Sudhir Kumar, a senior neurologist at Apollo Hospitals in...
Next week, several major companies, including Airtel, LIC, SBI, M&M, Sun Pharma, and Titan, are set to release their Q2 earnings reports.
The Indian corporate sector has reported earnings in line with expectations for the September quarter, boosting market sentiment. Several prominent companies, including Indian Oil Corporation, Adani Green Energy, and Hindustan Petroleum Corporation Limited, have...
Apollo clinicians and faculty members have been recognized in Stanford’s 2025 global ranking as among the top 2% of scientists worldwide.
Twelve clinicians and researchers from the Apollo Hospitals Group have been recognized in Stanford University's 2025 Global List of the Top 2% Scientists. This prestigious list, compiled by Stanford University in collaboration with Elsevier, identifies the top 2% of...
Apollo enhances its stroke care services by launching 9 additional laboratories.
Apollo Hospitals has recently announced the expansion of its Advanced Stroke Network in Tamil Nadu, making it the largest of its kind in the state. The network is designed to provide swift diagnosis and treatment for stroke patients in Chennai through a...
Medical experts sound alarm over increasing incidence of strokes in young people
On World Stroke Day, neurologists in Bengaluru sounded the alarm over the rising number of stroke cases among younger adults in India. This trend is concerning, as stroke was once primarily seen in older individuals. Experts attribute this shift to the adoption of...
ABRYSVO Secures Enhanced Public Funding in Multiple Canadian Provinces for the 2025-2026 Respiratory Syncytial Virus Season
Pfizer Canada has announced that its vaccine, ABRYSVO, for the prevention of Respiratory Syncytial Virus (RSV), will be publicly funded in multiple provinces and territories across Canada for the 2025-2026 season. This decision reflects the growing recognition of the...
Pfizer’s Accord for a Healthier World initiative is redefining traditional stability study protocols.
Pfizer's Accord for a Healthier World program is a comprehensive initiative aimed at addressing healthcare disparities by providing the company's full portfolio of medicines and vaccines on a not-for-profit basis to 45 lower-income countries. However, many of these...
The allergy treatment market is poised for growth, with major players like Pfizer, Sanofi, and AstraZeneca leading the charge, according to newstrail.com.
The allergy treatment market is expected to experience significant growth in the coming years, driven by increasing awareness and prevalence of allergies worldwide. According to a recent report, the market is anticipated to expand due to the rising demand for...
Pfizer’s COVID-19 vaccine side effect documents, normally sealed for 75 years, were disclosed 63 years ahead of schedule, exposing over 85,000 pages detailing various adverse reactions.
The medical community worldwide is reeling from a recent US court decision that has forced the Food and Drug Administration (FDA) and Pfizer to release confidential documents related to COVID-19 vaccine side effects. Initially, these documents were set to be made...
The Pfizer-Trump agreement may not be enough to save the pharmaceutical industry from its current woes.
The pharmaceutical industry is facing potential challenges despite the recent deal between Pfizer and the Trump administration. In November 2020, the US government announced a $1.95 billion deal with Pfizer to provide 100 million doses of its COVID-19 vaccine....
NICE has recommended the use of Pfizer’s Lorviqua for the treatment of lung cancer.
The National Institute for Health and Care Excellence (NICE) has recently recommended Pfizer's Lorviqua (lorlatinib) as a first-line treatment for certain types of lung cancer in England. This decision follows the publication of NICE's final guidance on the therapy,...
Pfizer partner Metsera highlights promising Phase II results for its GLP-1 candidate.
Metsera Therapeutics, a biotech company set to be acquired by Pfizer, has announced positive results from two Phase II trials for its GLP-1 receptor agonist, MSE-1018. The trials evaluated the efficacy and safety of MSE-1018 in patients with type 2 diabetes and...
Former Johnson & Johnson and Pfizer executive takes the reins as new CEO of Revision Skincare.
Lisa Paley, a seasoned consumer health executive, has been appointed as the CEO of Revision Skincare, a professional-grade skincare company based in Irving. Paley brings nearly 30 years of experience leading major global brands, including Haleon, GSK, Pfizer, and...
The Supreme Court has issued a notice to Fortis Hospital and other parties in response to a petition seeking compensation for a brain injury.
The Supreme Court of India has issued a notice to Fortis Hospital in response to a plea filed by an 8-year-old child, Devarsh Jain, seeking compensation of Rs 1350 crore for an alleged brain injury at birth in 2017. The child, who is in a vegetative state, approached...
Fortis’ S.L. Raheja Hospital achieves a significant milestone in cancer treatment with its first successful bone marrow transplant procedure.
S.L. Raheja Hospital, Mahim - A Fortis Associate, has successfully completed its first-ever Bone Marrow Transplant (BMT) at the Center of Excellence (COE) for Haemato-Oncology. The transplant was performed on a 61-year-old patient, Bijayentimala Devi, from Manipur,...
ICICI Securities has identified Apollo Hospitals and Metropolis as top choices in the healthcare sector, ahead of the release of Q2 results.
ICICI Securities has released its top picks in the healthcare sector, with Apollo Hospitals and Metropolis being the favored choices. This comes ahead of the Q2 results, which are expected to be released soon. The brokerage firm has maintained a "buy" rating on Apollo...
Statement released by Fortis Mohali regarding the health status of Punjabi singer Rajvir Jawanda.
Fortis Hospital in Mohali has issued a statement regarding the condition of Punjabi singer Rajvir Jawanda, who was admitted to the hospital after being shot in the United States. According to the statement, Jawanda is currently undergoing treatment at the hospital and...
Fortis in India plans to increase the number of its obesity clinics due to a surge in demand for weight-loss treatments, according to the company’s CEO.
India's Fortis Healthcare is planning to expand its obesity clinics across the country, according to its CEO. The move comes as the demand for weight-loss therapies is on the rise. The company aims to capitalize on the growing trend of people seeking medical help to...
Fortis introduces specialized orthopaedic and sports injury outpatient department in Srinagar
Fortis Healthcare has launched a monthly Orthopaedics and Sports Injury Outpatient Department (OPD) in Srinagar, aimed at providing specialized musculoskeletal and sports medicine care to residents. The OPD will be led by Dr. Tapish Shukla, an Associate Consultant in...
Hospitals are experiencing a significant change in their revenue streams, with oncology emerging as the most lucrative department.
India's top hospital chains, including Max Healthcare, Apollo Hospitals, and Fortis Healthcare, are experiencing a significant shift in their revenue mix, with oncology emerging as the fastest-growing and most profitable specialty. Oncology, once a niche segment, is...
Punjab’s Chief Minister is exhibiting signs of improvement while being closely monitored at Fortis Hospital.
Punjab Chief Minister Bhagwant Mann was admitted to Fortis Hospital in Mohali on Friday evening due to exhaustion and a low heart rate. The 51-year-old leader has been showing improvement, with stable vital signs and gradually improving blood parameters, according to...